254 related articles for article (PubMed ID: 29690575)
21. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the immune response and protective effects of rhesus macaques vaccinated with biodegradable nanoparticles carrying gp120 of human immunodeficiency virus.
Himeno A; Akagi T; Uto T; Wang X; Baba M; Ibuki K; Matsuyama M; Horiike M; Igarashi T; Miura T; Akashi M
Vaccine; 2010 Jul; 28(32):5377-85. PubMed ID: 20472029
[TBL] [Abstract][Full Text] [Related]
23. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
Jiang JQ; Patrick A; Moss RB; Rosenthal KL
J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
[TBL] [Abstract][Full Text] [Related]
24. Natural Immunity to HIV: a delicate balance between strength and control.
Poudrier J; Thibodeau V; Roger M
Clin Dev Immunol; 2012; 2012():875821. PubMed ID: 23304192
[TBL] [Abstract][Full Text] [Related]
25. Fluctuations in Blood Marginal Zone B-Cell Frequencies May Reflect Migratory Patterns Associated with HIV-1 Disease Progression Status.
Gauvin J; Chagnon-Choquet J; Poudrier J; Roger M;
PLoS One; 2016; 11(5):e0155868. PubMed ID: 27203285
[TBL] [Abstract][Full Text] [Related]
26. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
Jackson RJ; Worley M; Trivedi S; Ranasinghe C
Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
[TBL] [Abstract][Full Text] [Related]
27. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
28. Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information.
Artenstein AW; VanCott TC; Sitz KV; Robb ML; Wagner KF; Veit SC; Rogers AF; Garner RP; Byron JW; Burnett PR; Birx DL
J Infect Dis; 1997 Feb; 175(2):265-71. PubMed ID: 9203646
[TBL] [Abstract][Full Text] [Related]
29. Immunity in the female lower genital tract and the impact of HIV infection.
Ahmed SM; Al-Doujaily H; Johnson MA; Kitchen V; Reid WM; Poulter LW
Scand J Immunol; 2001; 54(1-2):225-38. PubMed ID: 11439171
[TBL] [Abstract][Full Text] [Related]
30. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers.
Broliden K; Hinkula J; Devito C; Kiama P; Kimani J; Trabbatoni D; Bwayo JJ; Clerici M; Plummer F; Kaul R
Immunol Lett; 2001 Nov; 79(1-2):29-36. PubMed ID: 11595287
[TBL] [Abstract][Full Text] [Related]
31. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women.
Hirbod T; Broliden K
J Intern Med; 2007 Jul; 262(1):44-58. PubMed ID: 17598814
[TBL] [Abstract][Full Text] [Related]
32. Mucosal serpin A1 and A3 levels in HIV highly exposed sero-negative women are affected by the menstrual cycle and hormonal contraceptives but are independent of epidemiological confounders.
Rahman S; Rabbani R; Wachihi C; Kimani J; Plummer FA; Ball TB; Burgener A
Am J Reprod Immunol; 2013 Jan; 69(1):64-72. PubMed ID: 22971020
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 and AIDS: what are protective immune responses?
Beattie T; Rowland-Jones S; Kaul R
J HIV Ther; 2002 May; 7(2):35-9. PubMed ID: 12553686
[TBL] [Abstract][Full Text] [Related]
34. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.
Fouts TR; Bagley K; Prado IJ; Bobb KL; Schwartz JA; Xu R; Zagursky RJ; Egan MA; Eldridge JH; LaBranche CC; Montefiori DC; Le Buanec H; Zagury D; Pal R; Pavlakis GN; Felber BK; Franchini G; Gordon S; Vaccari M; Lewis GK; DeVico AL; Gallo RC
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E992-9. PubMed ID: 25681373
[TBL] [Abstract][Full Text] [Related]
35. Innate immune system damage in human immunodeficiency virus type 1 infection. Implications for acquired immunity and vaccine design.
Howie S; Ramage R; Hewson T
Am J Respir Crit Care Med; 2000 Oct; 162(4 Pt 2):S141-5. PubMed ID: 11029383
[TBL] [Abstract][Full Text] [Related]
36. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
Leroux-Roels I; Koutsoukos M; Clement F; Steyaert S; Janssens M; Bourguignon P; Cohen K; Altfeld M; Vandepapelière P; Pedneault L; McNally L; Leroux-Roels G; Voss G
Vaccine; 2010 Oct; 28(43):7016-24. PubMed ID: 20728522
[TBL] [Abstract][Full Text] [Related]
37. Prospects for a Globally Effective HIV-1 Vaccine.
Excler JL; Robb ML; Kim JH
Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
[TBL] [Abstract][Full Text] [Related]
38. Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN).
Tomescu C; Abdulhaqq S; Montaner LJ
Clin Exp Immunol; 2011 May; 164(2):158-69. PubMed ID: 21413945
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium.
Nazli A; Kafka JK; Ferreira VH; Anipindi V; Mueller K; Osborne BJ; Dizzell S; Chauvin S; Mian MF; Ouellet M; Tremblay MJ; Mossman KL; Ashkar AA; Kovacs C; Bowdish DM; Snider DP; Kaul R; Kaushic C
J Immunol; 2013 Oct; 191(8):4246-58. PubMed ID: 24043886
[TBL] [Abstract][Full Text] [Related]
40. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
